No Detail Found!

Clinical profile of Behcet's Disease patients from Saudi Arabia: A Single Tertiary Centre, Retrospective Study

Author(s)
Hussam A. Alsulmi Department of Medicine, College of Medicine, Qassim University, Qassim, Saudi Arabia; Department of Medicine, Medical City, Qassim University, Qassim, Saudi Arabia
Faisal Aljuhani King Fahad specialist hospital Buraydah-Qassim, Qassim Health Cluster, Qassim, Saudi Arabia
Faisal Almutairi Department of Rheumatology, King Saud Hospital, Qassim Health Cluster, Qassim, Saudi Arabia
Abdullah H. Almutairi Department of Medicine, Al-Rass General Hospital, Qassim Health Cluster, Qassim, Saudi Arabi
Suliman Alharbi Department of Medicine, Qassim Health Cluster, Qassim, Saudi Arabi
Hamad AlSaeed Department of Surgery, Prince Mohammed Bin Abdulaziz hospital, 2nd cluster, Riyadh Saudi Arabia
Abdullah AlSamani Department of Medicine, King Fahad Medical City, 2nd Cluster, Riyadh, Saudi Arabia.
Abdulrahman F. Alsowinea Qassim health cluster, Qassim, Saudi Arabia
Abstract
Background: Behçet's disease (BD) is a multisystem vasculitis with heterogeneous phenotypes and notable geographic variability. Prior single-centre reports from Saudi Arabia are limited by small samples and inconsistent diagnostic capture. Methods: We conducted a retrospective cohort study (2015-2020) at a tertiary centre in central Saudi Arabia. Eligibility followed International Study Group (ISG) and International Criteria for Behçet's Disease (ICBD) definitions. To ensure diagnostic consistency, the full chart cohort (N=59) is summarized for transparency where variablelevel denominators were available. Data were abstracted via a structured instrument across socio-demographics, organsystem involvement, inflammatory markers (ESR/CRP), and therapies. Missingness was quantified a priori and handled via complete-case denominators. Proportions are reported with 95% Wilson CIs; small-cell comparisons used Fisher's exact tests aligned to prespecified contrasts (sex differences in mucocutaneous disease; ESR/CRP vs organ involvement). Results: The full cohort comprised 59 patients (male 72.9%): oral ulcers 72.9% (43/59; 95% CI 60.4-82.6), genital ulcers 55.9% (33/59; 43.3-67.8), ocular involvement 44.1% (26/59; 32.2-56.7) with anterior uveitis 28.8% (17/59; 18.8-41.4) and posterior uveitis 11.9% (7/59; 5.9-22.5), vascular involvement 13.6% (8/59; 7.0-24.5), arthritis 23.7% (14/59; 14.7-36.0). ESR and CRP were elevated in 18.6% (11/59; 10.7-30.4) and 22.0% (13/59; 13.4-34.1), respectively. Corticosteroids were prescribed in 72.9% (43/59; 60.4-82.6), colchicine 61.0% (36/59; 48.5-72.2), azathioprine 47.5% (28/59; 35.3-60.0). Sexstratified exact tests showed no significant difference for oral/genital ulcers; a female excess in cutaneous lesions lost robustness under small-sample-valid re-analysis and was treated as exploratory. Missing disease-duration data were substantial (35.6%). Findings were interpreted primarily within the oral-ulcer-confirmed analytic framework and secondarily against the full cohort for context. Conclusions: In central Saudi Arabia, BD presentations were dominated by mucocutaneous and ocular disease with comparatively modest vascular involvement. Inflammatory markers lacked stable associations with organ-system involvement. Given the modest sample, incomplete documentation for some fields, and small-cell structure, results are hypothesis-generating. This criteria-clean profile offers groundwork for a prospective, multi-centre registry with standardized phenotyping and time-locked biomarkers.
Publication Details
Page(s) 115-121
Published Journal: Journal of Pioneering Medical Sciences, Volume: 14, Issue: S2, Year: 2025

Request the full text from PASTIC

Keywords
Arthritis, Vasculitis, Arthritis, Saudi Arabia, Clinical manifestations, Recurrent oral ulcer, Behcet Disease
References
Park Y.E.,Cheon J.H. .2017 ."Updated treatment strategies for intestinal Behçet's disease.". Korean Journal of Internal Medicine, 377(2018) : 1-19.
Kirino Y.,Nakajima H. . ."Clinical and genetic aspects of Behçet's disease in Japan.". Internal Medicine, 18(2019) : 1199-1207.
Tong B. .2019 ."Immunopathogenesis of Behçet's disease." Frontiers in Immunology. , 00665 : 665.
Scherrer M.A.R. . ."Behçet's disease: review with emphasis on dermatological aspects.". Anais Brasileiros de Dermatologia, 92(2017) : 20177359-464.
Sfikakis P.P. . ."Anti-TNF therapy in the management of Behçet's disease-review and basis for recommendations.". Rheumatology (Oxford), 46(2007) : 736-741.
Kump L.I. . ."Behçet's disease: comparing 3 decades of treatment response at the National Eye Institute.". Canadian Journal of Ophthalmology, 43(2008) : 080-472.
'Angelo D,S. D .2014 .-factors-for -the- response- to-infliximabtherapy-in-patients-with-behcets-disease/.. " ACR/ARHP Annual Meeting, : .
Onal S. .2011 ."Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis.". Archives of Ophthalmology, 3(2011) : 288-294.
Kavandi H. .2016 ."Long-term efficacy and safety of interferon α-2a therapy in severe refractory ophthalmic Behçet's disease. " Clinical Rheumatology, 35(11) : 2765-2769.
Taylor S.R. .2011 ."Behçet disease: visual prognosis and factors influencing the development of visual loss.". American Journal of Ophthalmology, 05(2011) : 1059-1066.
Celiker H. .2018 ."Factors affecting relapse and remission in Behçet's uveitis treated with interferon alpha-2a.". Journal of Ocular Pharmacology and Therapeutics, 0059(2019) : 58-65.
.2006 .International Team for the Revision of the International Criteria for Behçet's Disease. "Evaluation of the International Criteria for Behçet's disease (ICBD)." Clinical and Experimental Rheumatology. , 42(suppl) : S13.
Zouboulis C.C. .2003 ."Onset signs, clinical course, prognosis, treatment and outcome of adult patients with AdamantiadesBehçet's disease in Greece." Clinical and Experimental Rheumatology. 4 suppl. 30, 21 : 2513-S26.
El-Garf A. .2018 ."Behçet's disease patterns and subsets in a cohort of Egyptian patients. " Egyptian Rheumatology, 05(2019) : 135-138.
Menyawi El,M.M. El .2009 ."Clinical features of Behçet's disease in Egypt.". Rheumatology International, 29 : 641-646.
El-Najjar A.R. .2014 ."Clinical characteristics and disease activity of Behçet's disease patients in Zagazig. Egypt." Egyptian Rheumatology, 11 : 191-196.
Arevalo J.F. .2014 .". American Journal of Ophthalmology, 10(2015) : 177-184.
. .Behçet's disease. , : .
Barnes C.G. . ."Treatment of Behçet's syndrome.". Rheumatology (Oxford), 45(2006) : 245-247.
Davatchi F. .2010 ."Behçet's disease: from east to west.". Clinical Rheumatology, 29 : 823-833.
Shakibi M.R. .2004 .". Journal of Medical Sciences, 120(2004) : 120-123.
Y.K. ,atertiary- ,- ,- ,- ,- ,- ,- . .sg/behcets-disease-experience-in-. , 33(2004) : 510-514.
Chin A.B.,Kumar A.S. . ."Behçet colitis." Clinical Colon and Rectal Surgery. , 28(2015) : 99-102.
Lopalco G.,Article ID .2017 ."Update on the medical management of gastrointestinal Behçet's disease.". Mediators of Inflammation, : .
Oner-Alibaz F. .2015 ."Behçet disease with vascular involvement.". Medicine (Baltimore), 94(6) : .
Saleh Z. . .. and T. Arayssi. "Update on the therapy of Behçet disease." Therapeutic Advances in Chronic Disease, 5(2014) : 112-134.
0

Citations

0

Downloads

66

Views